1,019 filings
Page 10 of 51
8-K
6vzpknnexj o9t
7 Dec 20
Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
1:22pm
4
v00ip
25 Nov 20
Cardiff Oncology / Vicki Kelemen ownership change
4:02pm
8-K
lesj qrk8
23 Nov 20
Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference
11:54am
8-K
wb94xnzs8ia
5 Nov 20
Cardiff Oncology Announces Third Quarter 2020 Results and Highlights
4:09pm
SC 13G
k1e7edsxcm5fsgmonx5
4 Nov 20
Cardiff Oncology / Venrock Healthcare Capital Partners III ownership change
4:54pm
8-K
d13d5q
20 Oct 20
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
11:59am
SC 13G
ga3k7i44smyuqk2lmltu
9 Oct 20
Cardiff Oncology / RA CAPITAL MANAGEMENT ownership change
4:29pm
3
52faq1
2 Oct 20
Cardiff Oncology / Rajeev M. Shah ownership change
4:30pm
8-K
xppm1op37
30 Sep 20
Cardiff Oncology Announces Proposed Public Offering
4:09pm
424B5
jutkodnpu
30 Sep 20
Prospectus supplement for primary offering
4:00pm
424B5
ocojkm f9
29 Sep 20
Prospectus supplement for primary offering
4:00pm
8-K
8pq93 rwbae4nh9toy
22 Sep 20
Regulation FD Disclosure
12:00am
8-K
dnywfrwwvoo6qyiv7hst
17 Sep 20
Other Events
11:18am
4
3o3mpu2
17 Sep 20
Cardiff Oncology / GARY W PACE ownership change
9:42am
8-K
tlq4ac
15 Sep 20
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
10:36am
8-K
x101hud0syex bdv5e2
14 Sep 20
Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
11:55am
SC 13G
t5qgjyb3e35a8 crrm
28 Aug 20
Cardiff Oncology / Opaleye Management ownership change
5:15pm
8-K
aeuh9uakxrq5yghcq9
11 Aug 20
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
4:04pm